Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 80% of Oncologists Conduct KRAS Gene Test: Merck Serono
August 30, 2010
- Miraca HD: Sales Up 10.4% to ¥41.4 Bil.
August 30, 2010
- Torii: Anti-HIV Drug Props Up Business
August 30, 2010
- Korosho to Promote Sharing of Knowhow on Use of Generics
August 30, 2010
- Takara Bio: Gene Engineering Segment Struggles
August 30, 2010
- Yakult: Elplat's Sales Up 31.4%
August 30, 2010
- Sawai: Sales to Dispending Pharmacies Up 59.2%
August 30, 2010
- A&T: Acquisition of ATWill Boosts Sales of In Vitro Diagnostics
August 30, 2010
- New MSD to Start Operation in October
August 30, 2010
- Taiyo Yakuhin: Sales Up 11.2% Despite Plant Shutdown
August 30, 2010
- How to Build a Winning Marketing Team
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
August 30, 2010
- Takeda Considers Acquisition of Overseas Company: Mr Hasegawa
August 30, 2010
- Astellas Ties Up with UMN Pharma to Jointly Develop Flu Vaccines
August 30, 2010
- Korosho to Conduct Large-Scale Trial for Antipsychotics
August 30, 2010
- MTPC Transfers Kerlong to sanofi-aventis
August 30, 2010
- Towa: Direct Sales Ratio Up by More Than 10 Points
August 30, 2010
- Proper Use of Antidepressants Discussed: Symposium
August 30, 2010
- Pola to Comarket Teika's Bedsore Treatment Sorenurse
August 30, 2010
- Nippon Chemiphar: Generics Account for 64% of Total Sales
August 30, 2010
- PMDA Calls For Regular Lab Tests in Patients Treated with SASP
August 30, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…